Photodynamic therapy is a cancer treatment modality with great potential but moderate clinical success. One reason for the sub-optimal clinical success is the limited knowledge about light distribution in tissues and lack of ways to monitor treatment real-time. Modulight has developed a laser platform for glioblastoma which will utilize real-time treatment monitoring based on spectral properties of the tissue and the drug. This therapy modality is based on photodynamic therapy with 5-aminolevulinic acid (5-ALA) primarily because the approved use of 5-ALA in fluorescence guided resections for glioblastoma and because of the known photobleaching properties of 5-ALA metabolite Protoporphyrin-IX (PPIX). Photobleaching means the photochemical alteration of a dye or a fluorophore in a way that it becomes permanently unable to fluoresce, and the real-time spectral monitoring is based on monitoring the intensity of PPIX fluorescence emission at 703 nm upon excitation with treatment wavelength 635 nm. Modulight glioblastoma platform enables monitoring PPIX fluorescence throughout the treatment to inspect the decline in fluorescence intensity. This photobleaching phenomenon represents the time region where the maximal therapeutic effect occurs so the ability to monitor this would ultimately enable optimizing the treatment time individually for each patient. Novel Modulight lasers are internet connected so that the treatment monitoring data can be immediately uploaded to cloud improving data management and review and possible future machine learning and AI based medicine.